ArticleThe American journal of psychiatry2024

Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia.

Marieke van der Pluijm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.